Акромегалія. Клінічні настанови Ендокринологічного товариства (2014 р.). Частина 1

Н. Б. Зелінська

Анотація


Мета полягає в розробці практичних клінічних настанов з акромегалії.

Учасники. Цільова група складається з голови, обраного підкомітетом Ендокринологічного товариства з клінічних настанов (Clinical Guidelines Subcommittee, CGS), п’яти експертів у цій галузі і методиста. Автори не отримали корпоративного фінансування або винагороди.

Настанови розроблені у співавторстві з Європейським ендокринологічним товариством.

Доказова база. Ці настанови на основі фактичних даних розроблено з використанням принципу GRADE (Grading of Recommendations, Assessment, Development, and Evaluation) — градації рекомендацій, оцінки та експертизи ступеня їх обґрунтованості — для опису як ступеня переконливості рекомендацій, так і якості доказової бази. Цільова група розглянула основне свідчення і два повноважних додаткових систематичних огляди.

Процес узгодження. Одна нарада групи, кілька конференц­зв’язків, а також спілкування електрон­ною поштою забезпечили досягнення консенсусу. Комітети та члени Ендокринологічного товариства, Європейського ендокринологічного товариства розглянули проекти цих керівних настанов.

Висновки. Використовуючи підхід на основі фактичних даних, ця настанова вирішує важливі клінічні питання, що стосуються визначення та управління акромегалією, зокрема відповідної біохімічної оцінки, терапевтичного алгоритму, як­то використання монотерапії або комбінованої терапії та ведення хворих під час вагітності (J. Clin. Endocrinol. Metab. — 2014. — 99. — Р. 3933—3951).


Повний текст:

PDF

Посилання


Abu Dabrh A.M., Asi N., Farah W. et al. Surgical interventions and medical treatments in treatment-naïve patients with acromegaly: systematic review and meta-analysis // J. Clin. Endocrinol. Metab. — 2014. — 99. — P. 4003—4014.

Al-Shraim M., Asa S.L. The 2004 World Health Organization classification of pituitary tumors: what is new? // Acta Neuropathol. — 2006. — 111. — P. 1—7.

Arafat A.M., Möhlig M., Weickert M.O. et al. Growth hormone response during oral glucose tolerance test: the impact of assay method on the estimation of reference values in patients with acromegaly and in healthy controls, and the role of gender, age, and body mass index // J. Clin. Endocrinol. Metab. — 2008. — 93. — P. 1254—1262.

Arosio M., Reimondo G., Malchiodi E. et al. Predictors of morbidity and mortality in acromegaly: an Italian survey // Eur. J. Endocrinol. — 2012. — 167. — P. 189—198.

Atkins D., Best D., Briss P.A. et al. Grading quality of evidence and strength of recommendations // BMJ. — 2004. — 328. — P. 1490—1494.

Attal P., Chanson P. Endocrine aspects of obstructive sleep apnea // J. Clin. Endocrinol. Metab. — 2010. — 95. — P. 483—495.

Bangham D.R., Gaines Das R.E., Schulster D. The international standard for human growth hormone for bioassay: calibration and characterization by international collaborative study // Mol. Cell Endocrinol. — 1985. — 42. — P. 269—282.

Barkan A.L., Beitins I.Z., Kelch R.P. Plasma insulin-like growth factor-I/somatomedin-C in acromegaly: correlation with the degree of growth hormone hypersecretion // J. Clin. Endocrinol. Metab. — 1988. — 67. — P. 69—73.

Barkan A.L., Stred S.E., Reno K. et al. Increased growth hormone pulse frequency in acromegaly // J. Clin. Endocrinol. Metab. — 1989. — 69. — P. 1225—1233.

Ben-Shlomo A., Pichurin O., Khalafi R. et al. Constitutive somatos­­tatin receptor subtype 2 activity attenuates GH synthesis // Endo­crinology. — 2013. — 154. — P. 2399—2409.

Ben-Shlomo A., Sheppard M.C., Stephens J.M. et al. Clinical, quality of life, and economic value of acromegaly disease control // Pituitary. — 2011. — 14. — P. 284—294.

Bidlingmaier M., Friedrich N., Emeny R.T. et al. Reference intervals for insulin-like growth factor-1 (igf-i) from birth to senescence: results from a multicenter study using a new automated chemiluminescence IGF-I immunoassay conforming to recent international recom­mend­ations // J. Clin. Endocrinol. Metab. — 2014. — 99. — P. 1712—1721.

Biermasz N.R., Dekker F.W., Pereira A.M. et al. Determinants of survival in treated acromegaly in a single center: predictive value of serial insulin-like growth factor I measurements // J. Clin. Endocrinol. Metab. — 2004. — 89. — P. 2789—2796.

Biermasz N.R., Pereira A.M., Smit J.W. et al. Morbidity after long-term remission for acromegaly: persisting joint-related complaints cause reduced quality of life // J. Clin. Endocrinol. Metab. — 2005. — 90. — P. 2731—2739.

Bolanowski M., Daroszewski J., Medra M., Zadrozna-Sliwka B. Bone mineral density and turnover in patients with acromegaly in relation to sex, disease activity, and gonadal function // J. Bone Miner Metab. — 2006. — 24. — P. 72—78.

Borson-Chazot F., Garby L., Raverot G. et al. Acromegaly induced by ectopic secretion of GHRH: a review 30 years after GHRH discovery // Ann. Endocrinol. (Paris). — 2012. — 73. — P. 497—502.

Caregaro L., Favaro A., Santonastaso P. et al. Insulin-like growth factor 1 (IGF-1), a nutritional marker in patients with eating disor­­ders // Clin. Nutr. — 2001. — 20. — P. 251—257.

Carmichael J.D., Bonert V.S., Mirocha J.M., Melmed S. The utility of oral glucose tolerance testing for diagnosis and assessment of treatment outcomes in 166 patients with acromegaly // J. Clin. Endocrinol. Metab. — 2009. — 94. — P. 523—527.

Clayton K.L., Holly J.M., Carlsson L.M. et al. Loss of the normal relationships between growth hormone, growth hormone-binding protein and insulin-like growth factor-I in adolescents with insulin-dependent diabetes mellitus // Clin. Endocrinol. (Oxf). — 1994. — 41. — P. 517—524.

Clemmons D.R. Consensus statement on the standardization and evaluation of growth hormone and insulin-like growth factor assays // Clin. Chem. — 2011. — 57. — P. 555—559.

Clemmons D.R., Van Wyk J.J., Ridgway E.C. et al. Evaluation of acromegaly by radioimmunoassay of somatomedin-C // N. Engl. J. Med. — 1979. — 301. — P. 1138—1142.

Colao A., Ferone D., Marzullo P., Lombardi G. Systemic complications of acromegaly: epidemiology, pathogenesis, and management // Endocr. Rev. — 2004. — 25. — P. 102—152.

Costa A.C., Rossi A., Martinelli C.E. Jr, et al. Assessment of disease activity in treated acromegalic patients using a sensitive GH assay: should we achieve strict normal GH levels for a biochemical cure? // J. Clin. Endocrinol. Metab. — 2002. — 87. — P. 3142—3147.

Daud S., Hamrahian A.H., Weil R.J. et al. Acromegaly with negative pituitary MRI and no evidence of ectopic source: the role of transphenoidal pituitary exploration? // Pituitary. — 2011. — 14. — P. 414—417.

Davi’ M.V., Dalle Carbonare L., Giustina A. et al. Sleep apnoea syndrome is highly prevalent in acromegaly and only partially reversible after biochemical control of the disease // Eur. J. Endocrinol. — 2008. — 159. — P. 533—540.

Dekkers O.M., Biermasz N.R., Pereira A.M. et al. Mortality in acromegaly: a metaanalysis // J. Clin. Endocrinol. Metab. — 2008. — 93. — P. 61—67.

Dimaraki E.V., Jaffe C.A., DeMott-Friberg R. et al. Acromegaly with apparently normal GH secretion: implications for diagnosis and fol­­low-up // J. Clin. Endocrinol. Metab. — 2002. — 87. — P. 3537—3542.

Dogan S., Atmaca A., Dagdelen S. et al. Evaluation of thyroid diseases and differentiated thyroid cancer in acromegalic patients // Endocrine. — 2014. — 45. — P. 114—121.

Dworakowska D., Gueorguiev M., Kelly P. et al. Repeated colonoscopic screening of patients with acromegaly: 15-year expe­rience identifies those at risk of new colonic neoplasia and allows for effective screening guidelines // Eur. J. Endocrinol. — 2010. — 163. — P. 21—28.

Ezzat S., Forster M.J., Berchtold P. et al. Acromegaly. Clinical and biochemical features in 500 patients // Medicine (Baltimore). — 1994. — 73. — P. 233—240.

Faje A.T., Barkan A.L. Basal, but not pulsatile, growth hormone secretion determines the ambient circulating levels of insulin-like growth factor-I // J. Clin. Endocrinol. Metab. — 2010. — 95. — P. 2486—2491.

Famini P., Maya M.M., Melmed S. Pituitary magnetic resonance imaging for sellar and parasellar masses: ten-year experience in 2598 patients // J. Clin. Endocrinol. Metab. — 2011. — 96. — P. 1633—1641.

Fava G.A., Sonino N., Morphy M.A. Psychosomatic view of endocrine disorders // Psychother. Psychosom. — 1993. — 59. — P. 20—33.

Fieffe S., Morange I., Petrossians P. et al. Diabetes in acromegaly, prevalence, risk factors, and evolution: data from the French Acro­megaly Registry // Eur. J. Endocrinol. — 2011. — 164. — P. 877—884.

Freda P.U., Reyes C.M., Nuruzzaman A.T. et al. Basal and glucose-suppressed GH levels less than 1 microg/L in newly diagnosed acromegaly // Pituitary. — 2003. — 6. — P. 175—180.

Frystyk J., Freda P., Clemmons D.R. The current status of IGF-I assays-a 2009 update // Growth Horm. IGF Res. — 2010. — 20. — P. 8—18.

Giustina A., Chanson P., Bronstein M.D. et al. A consensus on criteria for cure of acromegaly // J. Clin. Endocrinol. Metab. — 2010. — 95. — P. 3141—3148.

Giustina A., Veldhuis J.D. Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human // Endocr. Rev. — 1998. — 19. — P. 717—797.

Grynberg M., Salenave S., Young J., Chanson P. Female gonadal function before and after treatment of acromegaly // J. Clin. Endocrinol. Metab. — 2010. — 95. — P. 4518—4525.

Gullu B.E., Celik O., Gazioglu N., Kadioglu P. Thyroid cancer is the most common cancer associated with acromegaly // Pituitary. — 2010. — 13. — P. 242—248.

Hagiwara A., Inoue Y., Wakasa K. et al. Comparison of growth hormone-producing and non-growth hormone-producing pituitary adenomas: imaging characteristics and pathologic correlation // Radiology. — 2003. — 228. — P. 533—538.

Holdaway I.M., Bolland M.J., Gamble G.D. A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly // Eur. J. Endocrinol. — 2008. — 159. — P. 89—95.

Holdaway I.M., Rajasoorya R.C., Gamble G.D. Factors influencing mortality in acromegaly // J. Clin. Endocrinol. Metab. — 2004. — 89. — P. 667—674.

Jadresic A., Banks L.M., Child D.F. et al. The acromegaly syndrome. Relation between clinical features, growth hormone values and radiological characteristics of the pituitary tumours // Q. J. Med. — 1982. — 51. — P. 189—204.

Jayasena C.N., Wujanto C., Donaldson M. et al. Measurement of ba­­sal growth hormone (GH) is a useful test of disease activity in treated acromegalic patients // Clin. Endocrinol. (Oxf). — 2008. — 68. — P. 36—41.

Kan E., Kan E.K., Atmaca A. et al. Visual field defects in 23 acro­­megalic patients // Int. Ophthalmol. — 2013. — 33. — P. 521—525.

Kanis J.A., Gillingham F.J., Harris P. et al. Clinical and laboratory stu­­dy of acromegaly: assessment before and one year after treat­­ment // Q. J. Med. — 1974. — 43. — P. 409—431.

Karavitaki N., Fernandez A., Fazal-Sanderson V., Wass J.A. The value of the oral glucose tolerance test, random serum growth hormone and mean growth hormone levels in assessing the postoperative outcome of patients with acromegaly // Clin. Endocrinol. (Oxf). — 2009. — 71. — P. 840—845.

Karavitaki N., Turner H.E., Adams C.B. et al. Surgical debulking of pituitary macroadenomas causing acromegaly improves control by lanreotide // Clin. Endocrinol. (Oxf). — 2008. — 68. — P. 970—975.

Katznelson L., Atkinson J.L., Cook D.M. et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of acromegaly—2011 update: executive summary // Endocr. Pract. — 2011. — 17. — P. 636—646.

Kiseljak-Vassiliades K., Shafi S., Kerr J.M. et al. Clinical implications of growth hormone-secreting tumor subtypes // Endocrine. — 2012. — 42. — P. 18—28.

Lesse G.P., Fraser W.D., Farquharson R. et al. Gonadal status is an important determinant of bone density in acromegaly // Clin. Endocrinol. (Oxf). — 1998. — 48. — P. 59—65.

Lewitt M.S., Saunders H., Cooney G.J., Baxter R.C. Effect of human insulin-like growth factor-binding protein-1 on the half-life and action of administered insulin-like growth factor-I in rats // J. Endocrinol. — 1993. — 136. — P. 253—260.

Loeper S., Ezzat S. Acromegaly: re-thinking the cancer risk // Rev. Endocr. Metab. Disord. — 2008. — 9. — P. 41—58.

Lopes M.B. Growth hormone-secreting adenomas: pathology and cell biology // Neurosurg. Focus. — 2010. — 29. — P. E2.

Markkanen H., Pekkarinen T., Välimäki M.J. et al. Effect of sex and assay method on serum concentrations of growth hormone in patients with acromegaly and in healthy controls // Clin. Chem. — 2006. — 52. — P. 468—473.

Melmed S. Acromegaly pathogenesis and treatment // J. Clin. Invest. — 2009. — 119. — P. 3189—3202.

Melmed S. Medical progress: acromegaly // N. Engl. J. Med. — 2006. — 355. — P. 2558—2573.

Melmed S. Pathogenesis of pituitary tumors // Nat. Rev. Endocrinol. — 2011. — 7. — P. 257—266.

Melmed S., Braunstein G.D., Horvath E. et al. Pathophysiology of acromegaly // Endocr Rev. — 1983. — 4. — P. 271—290.

Melmed S., Casanueva F.F., Cavagnini F. et al. Guidelines for acromegaly management // J. Clin. Endocrinol. Metab. — 2002. — 87. — P. 4054—4058.

Melmed S., Casanueva F.F., Klibanski A. et al. A consensus on the diagnosis and treatment of acromegaly complications // Pituitary. — 2013. — 16. — P. 294—302.

Melmed S., Ezrin C., Kovacs K. et al. Acromegaly due to secretion of growth hormone by an ectopic pancreatic islet-cell tumor // N. Engl. J. Med. — 1985. — 312. — P. 9—17.

Mestron A., Webb S.M., Astorga R. et al. Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish Acromegaly Registry (Registro Espanol de Acro­­megalia, REA) // Eur. J. Endocrinol. — 2004. — 151. — P. 439—446.

Molitch M.E. Clinical manifestations of acromegaly // Endocrinol. Metab. Clin. North Am. — 1992. — 21. — P. 597—614.

Mosca S., Paolillo S., Colao A. et al. Cardiovascular involvement in patients affected by acromegaly: an appraisal // Int. J. Cardiol. — 2013. — 167. — P. 1712—1718.

Orme S.M., McNally R.J., Cartwright R.A., Belchetz P.E. Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group // J. Clin. Endocrinol. Metab. — 1998. — 83. — P. 2730—2734.

Pantanetti P., Sonino N., Arnaldi G., Boscaro M. Self-image and quality of life in acromegaly // Pituitary. — 2002. — 5. — P. 17—19.

Pokrajac A., Claridge A.G., Shakoor S.K., Trainer P.J. The octreotide test dose is not a reliable predictor of the subsequent response to somatostatin analogue therapy in patients with acromegaly // Eur. J. Endocrinol. — 2006. — 154. — P. 267—274.

Pokrajac A., Wark G., Ellis A.R. et al. Variation in GH and IGF-I assays limits the applicability of international consensus criteria to local practice // Clin. Endocrinol. (Oxf). — 2007. — 67. — P. 65—70.

Puder J.J., Nilavar S., Post K.D., Freda P.U. Relationship between disease-related morbidity and biochemical markers of activity in patients with acromegaly // J. Clin. Endocrinol. Metab. — 2005. — 90. — P. 1972—1978.

Puig-Domingo M., Resmini E., Gomez-Anson B. et al. Magnetic resonance imaging as a predictor of response to somatostatin analogs in acromegaly after surgical failure // J. Clin. Endocrinol. Metab. — 2010. — 95. — P. 4973—4978.

Reid T.J., Post K.D., Bruce J.N. et al. Features at diagnosis of 324 patients with acromegaly did not change from 1981 to 2006: acromegaly remains under-recognized and under-diagnosed // Clin. Endocrinol. (Oxf). — 2010. — 72. — P. 203—208.

Renehan A.G., Brennan B.M. Acromegaly, growth hormone and cancer risk // Best Pract. Res. Clin. Endocrinol. Metab. — 2008. — 22. — P. 639—657.

Ribeiro-Oliveira A. Jr, Barkan A. The changing face of acromegaly-advances in diagnosis and treatment // Nat. Rev. Endocrinol. — 2012. — 8. — P. 605—611.

Roemmler J., Gutt B., Fischer R. et al. Elevated incidence of sleep apnoea in acromegaly-correlation to disease activity // Sleep Breath. — 2012. — 16. — P. 1247—1253.

Rokkas T., Pistiolas D., Sechopoulos P. et al. Risk of colorectal neoplasm in patients with acromegaly: a meta-analysis // World J. Gastroenterol. — 2008. — 14. — P. 3484—3489.

Sakharova A.A., Dimaraki E.V., Chandler W.F., Barkan A.L. Clinically silent somatotropinomas may be biochemically active // J. Clin. Endocrinol. Metab. — 2005. — 90. — P. 2117—2121.

Sherlock M., Aragon Alonso A., Reulen R.C. et al. Monitoring disease activity using GH and IGF-I in the follow-up of 501 patients with acromegaly // Clin. Endocrinol. (Oxf). — 2009. — 71. — P. 74—81.

Sherlock M., Ayuk J., Tomlinson J.W. et al. Mortality in patients with pituitary disease // Endocr. Rev. — 2010. — 31. — P. 301—342.

Sherlock M., Reulen R.C., Aragon-Alonso A. et al. A paradigm shift in the monitoring of patients with acromegaly: last available growth hormone may overestimate risk // J. Clin. Endocrinol. Metab. — 2014. — 99. — P. 478—485.

Sughrue M.E., Chang E.F., Gabriel R.A. et al. Excess mortality for patients with residual disease following resection of pituitary adenomas // Pituitary. — 2011. — 14. — P. 276—383.

Swiglo B.A., Murad M.H., Schünemann H.J. et al. A case for clarity, consistency, and helpfulness: state-of-the-art clinical practice guidelines in endocrinology using the grading of recommendations, assessment, development, and evaluation system // J. Clin. Endo­­crinol. Metab. — 2008. — 93. — P. 666—673.

Tagliafico A., Resmini E., Nizzo R. et al. The pathology of the ulnar ner­­ve in acromegaly // Eur. J. Endocrinol. — 2008. — 159. — P. 369—373.

Tagliafico A., Resmini E., Nizzo R. et al. Ultrasound measurement of median and ulnar nerve cross-sectional area in acromegaly // J. Clin. Endocrinol. Metab. — 2008. — 93. — P. 905—909.

Tan K.C., Shiu S.W., Janus E.D., Lam K.S. LDL subfractions in acromegaly: relation to growth hormone and insulin-like growth factor-I // Atherosclerosis. — 1997. — 129. — P. 59—65.

Terzolo M., Reimondo G., Gasperi M. et al. Colonoscopic screening and follow-up in patients with acromegaly: a multicenter study in Italy // J. Clin. Endocrinol. Metab. — 2005. — 90. — P. 84—90.

Thorner M.O., Martin W.H., Rogol A.D. et al. Rapid regression of pituitary prolactinomas during bromocriptine treatment // J. Clin. Endocrinol. Metab. — 1980. — 51. — P. 438—445.

Vierimaa O., Georgitsi M., Lehtonen R. et al. Pituitary adenoma predisposition caused by germline mutations in the AIP gene // Science. — 2006. — 312. — P. 1228—1230.

Vitale G., Pivonello R., Auriemma R.S. et al. Hypertension in acromegaly and in the normal population: prevalence and deter­minants // Clin. Endocrinol. (Oxf). — 2005. — 63. — P. 470—476.

Wassenaar M.J., Biermasz N.R., Hamdy N.A. et al. High prevalence of vertebral fractures despite normal bone mineral density in patients with long-term controlled acromegaly // Eur. J. Endocrinol. — 2011. — 164. — P. 475—483.

Weber M.M., Auernhammer C.J., Lee P.D. et al. Insulin-like growth factors and insulin-like growth factor binding proteins in adult patients with severe liver disease before and after orthotopic liver transplantation // Horm. Res. — 2002. — 57. — P. 105—112.

Wolinski K., Czarnywojtek A., Ruchala M. Risk of thyroid nodular disease and thyroid cancer in patients with acromegaly-meta-analysis and systematic review // PLoS One. — 2014. — 9. — P. 88787.


Посилання

  • Поки немає зовнішніх посилань.


© Український журнал дитячої ендокринології, 2018
© ПП «ІНПОЛ ЛТМ», 2018